Title: Cilastatin
CAS Registry Number: 82009-34-5
CAS Name: (2
Z)-7-[[(2
R)-2-Amino-2-carboxyethyl]thio]-2-[[[(1
S)-2,2-dimethylcyclopropyl]carbonyl]amino]-2-heptenoic acid
Manufacturers' Codes: MK-791
Molecular Formula: C16H26N2O5S
Molecular Weight: 358.45
Percent Composition: C 53.61%, H 7.31%, N 7.82%, O 22.32%, S 8.95%
Literature References: Prevents renal metabolism of penem and carbapenem antibiotics by specific and reversible dehydropeptidase I inhibition. Synthesis and combination with thienamycins: D. W. Graham
et al., EP 48301; H. Kropp
et al., EP 48025 (both 1982 to Merck & Co.),
C.A. 97, 145271b, 145270a (1982). Combination with penems: F. M. Kahan, H. Kropp,
EP 72014 (1983 to Merck & Co.),
C.A. 99, 70272h (1983). The articles cited below discuss the activity of cilastatin alone and in combination with imipenem,
q.v. Dipeptidase inhibition, pharmacokinetics: S. R. Norrby
et al., Antimicrob. Agents Chemother. 23, 300 (1983). Stimulation of granulocyte function: H. Gnarpe
et al., ibid. 25, 179 (1984). HPLC determn in serum: C. M. Myers, J. L. Blumer,
ibid. 26, 78 (1984). Enhances intrathecal and ocular penetration of imipenem: A. W. Chow
et al., ibid. 23, 634 (1983) and K. R. Finlay
et al., Invest. Ophthalmol. Visual Sci. 24, 1147 (1983), respectively. In experimental meningitis: D. E. Washburn
et al., J. Antimicrob. Chemother. 12, 39 (1983). Series of articles on pharmacokinetics, safety and tolerance and efficacy of cilastatin/imipenem:
ibid. 12, Suppl. D, 1-155 (1983);
Infection 14, Suppl. 2, S111-S180 (1986).
Derivative Type: Sodium salt
CAS Registry Number: 81129-83-1
Synonyms: Cilastatin sodium
Molecular Formula: C16H25N2NaO5S
Molecular Weight: 380.43
Percent Composition: C 50.51%, H 6.62%, N 7.36%, Na 6.04%, O 21.03%, S 8.43%
Properties: Off-white to yellowish-white hygroscopic, amorphous solid. pKa1 2.0; pKa2 4.4; pKa3 9.2. Very sol in water, methanol.
pKa: pKa1 2.0; pKa2 4.4; pKa3 9.2
Therap-Cat: Antibacterial adjunct (dipeptidase inhibitor).
Keywords: Antibacterial Adjuncts; Renal Dipeptidase Inhibitors.